Zuclopenthixol

NERVOUS SYSTEM

Key facts

Zuclopenthixol is a drug catalogued in DrugCentral. DrugCentral lists 6 molecular targets, including HTR6, HDAC6 and HTR2A. Recorded indications include Schizophrenia.

• Molecular targets: HTR6, HDAC6, HTR2A and ADRA1A (6 listed in DrugCentral).
• Indications: Schizophrenia.
• ATC code: N05AF05 (Thioxanthene derivatives).
• Molecular formula: C22H25ClN2OS; molecular weight 400.98 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Schizophrenia

Mechanism & targets

Molecular targets (6)

Target	Gene	Action	Activity
5-hydroxytryptamine receptor 6	HTR6	unknown	Ki 6.77
Histone deacetylase 6	HDAC6	unknown	IC50 5.47
5-hydroxytryptamine receptor 2A	HTR2A	unknown	—
Alpha-1A adrenergic receptor	ADRA1A	unknown	—
D(1A) dopamine receptor	DRD1	antagonist	—
D(2) dopamine receptor	DRD2	antagonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
—	UK Medicines and Healthcare Products Regulatory Agency (MHRA)	—	—

ATC classification

ATC code	Therapeutic hierarchy
N05AF05	NERVOUS SYSTEM › PSYCHOLEPTICS › ANTIPSYCHOTICS › Thioxanthene derivatives

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• Swissmedic label: CYP2D6

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Blood prolactin abnormal	1118.2
Anosognosia	1108.9
Disturbance in social behaviour	1037.4
Sexual dysfunction	978.1
Metabolic disorder	916.0
Dystonia	820.8
Personality change	816.3
Sedation	667.1
Dyskinesia	639.0
Suicide attempt	502.4
Schizophrenia	397.5
Blood glucose increased	372.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Zuclopenthixol is on its molecule page.

• Molecular formula: C₂₂H₂₅ClN₂OS
• Molecular weight: 400.98 g/mol
• CAS number: —
• InChIKey: WFPIAZLQTJBIFN-DVZOWYKESA-N
• PubChem CID: 12454

OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Zuclopenthixol used for?

DrugCentral lists the following indications for Zuclopenthixol: Schizophrenia.

How does Zuclopenthixol work?

Its molecular targets in DrugCentral include HTR6, HDAC6, HTR2A and ADRA1A.

What is the chemical formula of Zuclopenthixol?

Zuclopenthixol has the molecular formula C22H25ClN2OS and a molecular weight of 400.98 g/mol.

Sources

• DrugCentral drug card 2877 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL53904 — compound record and bioactivity
• PubChem CID 12454 — chemical identifiers
• DrugBank DB01624 — drug record
• FDA UNII 47ISU063SG — substance identity
• UniProt P50406 (HTR6) — target protein
• UniProt Q9UBN7 (HDAC6) — target protein
• UniProt P28223 (HTR2A) — target protein
• UniProt P35348 (ADRA1A) — target protein
• UniProt P21728 (DRD1) — target protein
• UniProt P14416 (DRD2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.